FindTrial
Sign In

To evaluate the efficacy of Eranda taila Matrabasti with Tamsulosin tablet in the management of vatashtheela (mutraghata) w.s.r to benign prostatic hyperplasia.

Randomized controlled clinical study of Eranda taila Matrabasti with Tamsulosin tablet in the management of vatashtheela (mutraghata) w.s.r. to benign prostatic hyperplasia. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/05/086983
Enrollment
64
Registered
2025-05-15
Start date
Unknown
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N401- Benign prostatic hyperplasia withlower urinary tract symptoms

Interventions

None listed

Sponsors

Matoshri Asarabai Darade Ayurved College,Babhulgaon,Yeola
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Age group between 40 yrs to 70 yrs. 2.Classical sign and symptoms of Mutraghata (BPH). 3.USG of prostate suggestive of increased size and weight. 4.Significant post voidal urine of greater than 90CC upto 200 CC.

Exclusion criteria

Exclusion criteria: 1.Age below 40 yrs and above 70 yrs. 2.Acute retention of urine. 3.Severe urinary calculi with significant obstructive uropathy. 5.Renal failure. 6.Systemic diseases like HIV, Hepatitis, T2DM.

Design outcomes

Primary

MeasureTime frame
The parameters will be noted down before and after treatment. The patient will be diagnosed based on symptoms of Vatashteela (Mutraghata) explained in Ayurvdic and Modern texts. 1.Incomplete Emptying 2.Frequency 3.Intermittency 4.Urgency 5.Weak Stream 6.Straining 7.NocturiaTimepoint: 1st,14th,21st,28th—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactDr Kiran Uttam Sirsat

Matoshri Asarabai Darade Ayurved College Babhulgaon Yeola

manojsonaje@gmail.com9423932283

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026